PCUTT115
Oncology Nursing Update Lung Cancer Edition, Issue 1, 2015
OVERVIEW OF ACTIVITY
Lung cancer is one of the most rapidly evolving fields in oncology nursing and is a major public health concern. In
2015, lung cancer will culminate in 221,200 new cases and an estimated 158,040 deaths in the United States.
Progress in the screening, prevention and treatment of this disease has been limited, and approximately 85% of
patients who develop lung cancer will die of it. Traditional chemotherapy, surgery and radiation therapy have had a
modest effect on long-term outcomes. However, the advent of novel therapies has led to recent improvements in
disease-free and overall survival in select patient populations. Additionally, published results from ongoing clinical
CaCU115
ASCOGI15
TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows, gastrointestinal surgeons and other healthcare providers involved in the treatment of gastrointestinal (GI) cancers.
SABCS15
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of breast cancer.
OVERVIEW OF ACTIVITY
Breast cancer remains the most frequently diagnosed cancer in women, and in 2014 in the United States alone the disease culminated in an estimated 232,670 new cases and 40,000 deaths. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, such that only 5% of women have identifiable distant metastases at primary diagnosis. Consequently, the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.
5MJCASH2015/2
Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.
COCP15/2
OVERVIEW OF ACTIVITY
In 2015 in the United States alone it is estimated that 220,800 new cases of prostate cancer (PCa) will occur. With an estimated 27,540 deaths in 2015, PCa is the second-leading cause of cancer death in men. The disease has a tremendous global impact and has become the center of extensive ongoing clinical research. For this reason, the clinical management of PCa is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets relevant to the continuous delivery of quality cross-functional care.
ASHMM15
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.
OVERVIEW OF ACTIVITY
5MJCASH2015
Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.
5MJCASH2015/1
Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.
ASHNHL15
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.
OVERVIEW OF ACTIVITY
YIRMultitumor14/CME
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.
OVERVIEW OF ACTIVITY
GICU214
OVERVIEW OF ACTIVITY
BCUS1214
OVERVIEW OF ACTIVITY
COCP15/1
OVERVIEW OF ACTIVITY
Nearly one million men each year are newly diagnosed with prostate cancer (PCa), making it the fifth most common cancer in both sexes combined and the second most common among men worldwide. In 2014 in the United States alone it is estimated that the disease will culminate in 233,000 new cases and 29,480 deaths. As such, PCa has a tremendous global impact and has become the center of extensive ongoing clinical research. For this reason, the clinical management of PCa is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets relevant to the continuous delivery of quality cross-functional care.